Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200 Day Moving Average - Time to Sell?

Key Points

• Shares slipped below their 200‑day moving average — AVXL traded as low as $3.23 and last at $3.26 versus a 200‑day MA of $4.67 (50‑day MA $3.80), signalling weakening technical momentum.
• Analyst coverage is mixed (two Buys, one Hold, one Sell) with a consensus rating of Hold and an average price target of $22.00, implying substantial upside expectations despite current weakness.
• The company is a clinical‑stage biotech with a market cap around $302M and negative EPS (latest quarter -$0.06; FY forecast -$0.33), and its lead candidate blarcamesine is in trials for Alzheimer’s and Parkinson’s disease dementia, underscoring both potential and clinical-stage risk.

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.67 and traded as low as $3.23. Anavex Life Sciences shares last traded at $3.26, with a volume of 618,635 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AVXL. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 10th. Weiss Ratings raised Anavex Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, April 22nd. Wall Street Zen upgraded Anavex Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, February 14th. Finally, D. Boral Capital reissued a "buy" rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Anavex Life Sciences presently has a consensus rating of "Hold" and an average target price of $22.00.

Anavex Life Sciences Stock Down 3.3%

The stock has a 50-day simple moving average of $3.80 and a 200-day simple moving average of $4.67. The firm has a market capitalization of $302.11 million, a PE ratio of -7.09 and a beta of 1.18.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. Equities analysts forecast that Anavex Life Sciences Corp. will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

Several large investors have recently modified their holdings of AVXL. State Street Corp increased its stake in shares of Anavex Life Sciences by 33.4% in the fourth quarter. State Street Corp now owns 4,383,406 shares of the biotechnology company's stock worth $15,605,000 after purchasing an additional 1,096,288 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Anavex Life Sciences by 17,921.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 744,469 shares of the biotechnology company's stock worth $2,650,000 after purchasing an additional 740,338 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Anavex Life Sciences by 187.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company's stock worth $3,108,000 after purchasing an additional 569,579 shares in the last quarter. Summit Financial LLC increased its stake in shares of Anavex Life Sciences by 103.3% in the fourth quarter. Summit Financial LLC now owns 903,392 shares of the biotechnology company's stock worth $3,216,000 after purchasing an additional 459,121 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new position in shares of Anavex Life Sciences in the fourth quarter worth about $1,310,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company's lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease dementia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.